Hyperuricemia & Gout Preparations
| Drug | Dosage | Remarks |
|---|---|---|
| Allopurinol | 200-300 mg PO 12-24 hourly |
Adverse Reactions
|
| Febuxostat |
Uric nephrolithiasis: 80 mg PO 24 hourly |
Adverse Reactions
|
|
Pinene/Camphene/Cineol/ Fenchone/Borneol/Anethol |
1-2 cap PO 8 hourly |
Special Instructions
|
Other Drugs Acting on the Genito-Urinary System
| Drug | Dosage | Remarks |
|---|---|---|
| Potassium citrate |
Mild-moderate hypocitraturia: 10 mEq PO 8 hourly or 15 mEq PO 12 hourly or 30 mEq PO 24 hourly Severe hypocitraturia: 15 mEq PO 6 hourly or 20 mEq PO 8 hourly or 30 mEq PO 12 hourly or 60 mEq PO 24 hourly |
Adverse Reactions
|
|
Sambong (Blumea balsamifera Leaf) |
1,000 mg PO 8 hourly or 40-50 mg/kg/day PO in 3 divided doses |
Adverse Reactions
|
| Tiopronin |
Initial dose: 800 mg PO 8 hourly Average dose: 1,000 mg/day PO in 3 divided doses |
Adverse Reactions
|
Supplements & Adjuvant Therapy
| Drug | Dosage | Remarks |
|---|---|---|
| Orthosiphonis herba/Plantago major folium/Sericocalyx folium/Sonchus arvensis folium | 1-2 cap PO 8 hourly |
Special Instructions
|
| Phyllantus niruri/Rosmarinus officinalis/Ocimum basilicum | 1 cap PO 24 hourly | |
| Phytin/L-methionine/Vitamin A/Zinc |
JJ catheter calcification: 3 capsules PO 24 hourly x 4 months Infectious lithiasis/struvite: 2 capsules PO 24 hourly x 4 months |
Special Instructions
|
| Theobromine/Vitamin A/Zinc | Uric acid lithiasis: 2 capsules PO 24 hourly x 4 months |
Disclaimer
All dosage recommendations are for non-pregnant and non-breastfeeding women, and non-elderly adults with normal renal and hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
